Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.

被引：1
|
作者：
Waddell, Tom Samuel
Chau, Ian
Peckitt, Clare
Gonzalez, David
Wotherspoon, Andrew
Patel, Bijal
Middleton, Gary William
Wadsley, Jonathan
Ferry, David
Mansoor, Wasat
Crosby, Tom David Lewis
Coxon, Fareeda Y.
Smith, David
Waters, Justin S.
Iveson, Timothy
Falk, Stephen
Slater, Sarah
Okines, Alicia Frances Clare
Cunningham, David
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Royal Marsden NHS Fdn Trust, Surrey, England
[3] St Lukes Canc Ctr, Guildford, Surrey, England
[4] Weston Pk Hosp, Sheffield, S Yorkshire, England
[5] New Cross Hosp, Wolverhampton, England
[6] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[7] Velindre Hosp NHS Fdn Trust, Cardiff, Wales
[8] Northem Ctr Canc Care, Newcastle, NSW, Australia
[9] Clatterbridge Ctr Oncol NHS Fdn Trust, Wirral, Merseyside, England
[10] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
[11] Canc Res UK Clin Ctr, Southampton, Hants, England
[12] Bristol Haematol & Oncol Ctr, Bristol, Avon, England
[13] Barts & London NHS Trust, London, England
[14] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4067
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4067
引用
收藏
页数：1
相关论文
共 37 条
  • [31] Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
    Vamvakas, L.
    Karampeazis, A.
    Ardavanis, A.
    Souglakos, I.
    Kalbakis, K.
    Vardakis, N.
    Kouroussis, Ch.
    Malamos, N.
    Varthalitis, I.
    Mavroudis, D.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S49 - S49
  • [32] Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134).
    Jensen, Roxanne E.
    Zheng, Yue
    Atkins, Michael B.
    Chmielowski, Bartosz
    Tarhini, Ahmad A.
    Truong, Thach-Giao
    Davar, Diwakar
    O'Rourke, Mark Allen
    Curti, Brendan D.
    Brell, Joanna M.
    Kendra, Kari Lynn
    Ikeguchi, Alexandra
    Lee, Sandra J.
    Potosky, Arnold L.
    Wolchok, Jedd D.
    Ribas, Antoni
    Kirkwood, John M.
    Wagner, Lynne I.
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248)
    Ringash, Jolie
    Waldron, John N.
    Siu, Lillian L.
    Martino, Rosemary
    Winquist, Eric
    Wright, Jim R.
    Nabid, Abdenour
    Hay, John H.
    Hammond, Alex
    Sultanem, Khalil
    Hotte, Sebastien
    Leong, Carson
    El-Gayed, Ali Abdel Halim
    Naz, Farah
    Ramchandar, Kevin
    Owen, Tim E.
    Montenegro, Alexander
    O'Sullivan, Brian
    Chen, Bingshu E.
    Parulekar, Wendy R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091)
    Reijneveld, Jaap C.
    Coens, Corneel
    Taphoorn, Martin J. B.
    Smitt, Peter Sillevis
    Clement, Paul M.
    Idbaih, Ahmed
    de Vos, Filip
    Klein, Martin
    Wick, Wolfgang
    Mulholland, Paul
    Lewis, Joanne
    Golfinopoulos, Vassilis
    Bottomley, Andrew
    van den Bent, Martin
    NEURO-ONCOLOGY, 2017, 19 : 203 - 203
  • [35] Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer
    Chau, I.
    Al-Batran, S-E.
    Luft, A.
    Kowalyszyn, R. D.
    Hernandez, C. A.
    Pfeiffer, P.
    Wojcik, E.
    Bodoky, G.
    Madi, A.
    Brenner, B.
    De Vita, F.
    Folprecht, G.
    Peltola, K.
    Lorenzen, S.
    Denlinger, C.
    Liepa, A.
    Das, M.
    Wei, R.
    Fuchs, C. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522
    Minh Tam Truong
    Zhang, Qiang
    Rosenthal, David I.
    List, Marcie
    Axelrod, Rita
    Sherman, Eric
    Weber, Randal
    Phuc Felix Nguyen-Tan
    El-Naggar, Adel
    Konski, Andre
    Galvin, James
    Schwartz, David
    Trotti, Andy
    Silverman, Craig
    Singh, Anurag
    Godette, Karen
    Bonner, James A.
    Jones, Christopher U.
    Garden, Adam S.
    Shenouda, George
    Matthiesen, Chance
    Quynh-Thu Le
    Bruner, Deborah
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (04): : 687 - 699
  • [37] Differences in the quality of life (QoL) and functional outcomes of treatment between HPV associated (HPV plus ) and HPV-patients receiving primary chemoradiotherapy in PET-NECK - a multi-centre randomized phase III controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNC) treated with primary radical chemoradiotherapy (CRT)
    Mehanna, H.
    Wong, W. L.
    McConkey, C. C.
    Rahman, J. K.
    Robinson, M.
    Hartley, A.
    Nutting, C.
    Powell, N.
    Al-Booz, H.
    Robinson, M.
    Junor, E.
    Hulme, C.
    Smith, A. F.
    Hall, P.
    Dunn, J. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S715 - S715
1234